Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2024 10:17 ET | Source: Research and Markets

Metastatic Castration-Resistant Prostate Cancer in Major Global Markets, 2024-2034: Drug Sales, Epidemiology Forecast, Trends, Unmet Needs, and More

Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Castration-Resistant Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report...
April 18, 2024 09:11 ET | Source: Research and Markets

World Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugs

Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
January 04, 2024 18:33 ET | Source: Research and Markets

Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032

Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This...
July 14, 2021 05:03 ET | Source: Research and Markets

Global Prostate Cancer Clinical Landscape Market Report 2021: Treatments, Epidemiology, Marketed Drugs, Pipeline Drugs, Regulatory Events, Clinical Trials, Drug Assessment, Future Trends

Dublin, July 14, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Prostate Cancer" report has been added to ResearchAndMarkets.com's offering. The publisher estimates that in 2018, there were 1.3...
October 29, 2019 09:00 ET | Source: Druggability Technologies Holdings Ltd

DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT 45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer

BUDAPEST, Hungary, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces the first subject dosed in a two-part Phase I trial to evaluate the pharmacokinetics,...
August 07, 2019 20:00 ET | Source: Telix Pharmaceuticals Limited

Telix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study

MELBOURNE, Australia and SYDNEY, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...